4,185 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Gabelli Funds LLC

Gabelli Funds LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,185 shares of the biopharmaceutical company’s stock, valued at approximately $387,000.

Several other large investors have also recently added to or reduced their stakes in GILD. Bridgewater Associates LP lifted its stake in shares of Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company’s stock valued at $42,577,000 after purchasing an additional 253,994 shares in the last quarter. Ontario Teachers Pension Plan Board grew its stake in Gilead Sciences by 54.6% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company’s stock worth $3,422,000 after buying an additional 13,086 shares during the period. Rossby Financial LCC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at $232,000. Canada Post Corp Registered Pension Plan acquired a new position in shares of Gilead Sciences during the 4th quarter valued at $4,791,000. Finally, Belpointe Asset Management LLC boosted its position in Gilead Sciences by 108.3% during the 4th quarter. Belpointe Asset Management LLC now owns 8,527 shares of the biopharmaceutical company’s stock worth $788,000 after purchasing an additional 4,433 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 302,785 shares of company stock worth $30,540,875. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $104.49 on Monday. The company’s fifty day moving average is $109.16 and its two-hundred day moving average is $97.63. The firm has a market capitalization of $130.10 billion, a price-to-earnings ratio of 282.40, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.02%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GILD. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.